Eversept Partners LP cut its stake in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 77.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 27,089 shares of the biotechnology company’s stock after selling 93,838 shares during the quarter. Eversept Partners LP owned about 0.09% of AnaptysBio worth $1,502,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently bought and sold shares of ANAB. Los Angeles Capital Management LLC raised its stake in shares of AnaptysBio by 1.5% in the fourth quarter. Los Angeles Capital Management LLC now owns 15,101 shares of the biotechnology company’s stock valued at $732,000 after acquiring an additional 225 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of AnaptysBio by 24.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 263 shares during the period. Larson Financial Group LLC grew its holdings in AnaptysBio by 21.2% during the 4th quarter. Larson Financial Group LLC now owns 1,624 shares of the biotechnology company’s stock valued at $79,000 after purchasing an additional 284 shares during the last quarter. Susquehanna Portfolio Strategies LLC grew its holdings in AnaptysBio by 1.4% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 35,948 shares of the biotechnology company’s stock valued at $1,743,000 after purchasing an additional 500 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its position in AnaptysBio by 5,864.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 821 shares during the period.
AnaptysBio Price Performance
AnaptysBio stock opened at $53.61 on Tuesday. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of -49.64 and a beta of 0.68. AnaptysBio, Inc. has a 1 year low of $11.40 and a 1 year high of $72.36. The firm has a 50-day moving average of $58.28 and a two-hundred day moving average of $57.64.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on ANAB. Leerink Partners set a $90.00 target price on AnaptysBio in a research report on Friday, May 15th. Barclays increased their price target on AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. HC Wainwright initiated coverage on AnaptysBio in a research note on Wednesday, June 10th. They set a “buy” rating and a $95.00 price target for the company. Piper Sandler dropped their price objective on AnaptysBio from $95.00 to $93.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Finally, UBS Group upped their price objective on AnaptysBio from $60.00 to $76.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, AnaptysBio has a consensus rating of “Moderate Buy” and a consensus price target of $82.00.
View Our Latest Analysis on AnaptysBio
AnaptysBio Company Profile
AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.
The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.
Featured Stories
- Five stocks we like better than AnaptysBio
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.
